Mechanism of Action of Doxepin
At the low doses used for insomnia (3-6 mg), doxepin works primarily as a highly selective and potent histamine H1 receptor antagonist, which promotes sleep initiation and maintenance by blocking the wake-promoting effects of histamine in the central nervous system. 1
Dose-Dependent Pharmacology
The mechanism of doxepin is fundamentally different depending on the dose:
Low-Dose Mechanism (1-6 mg for Insomnia)
- Selective H1 antagonism: At these ultra-low doses, doxepin binds with subnanomolar affinity specifically to histamine H1 receptors 2, 3
- Minimal other receptor activity: At 3-6 mg doses, there is negligible anticholinergic, antinoradrenergic, or antiserotonin activity 4
- This selectivity explains why low-dose doxepin avoids the side effects seen with higher antidepressant doses 5
Higher-Dose Mechanism (75-300 mg for Depression)
At antidepressant doses, doxepin acts through multiple mechanisms 1:
- Norepinephrine reuptake inhibition: Prevents deactivation of norepinephrine at synapses
- Anticholinergic effects: Blocks muscarinic receptors
- Antiserotonin activity: Antagonizes serotonin receptors
- Antihistamine effects: H1 blockade (but accompanied by other receptor effects)
Clinical Implications of the Mechanism
The H1 antagonism at low doses specifically targets sleep maintenance rather than sleep onset 5, 6. This is because:
- Histamine plays a key role in maintaining wakefulness throughout the sleep period
- Blocking H1 receptors reduces wake after sleep onset (WASO) and increases total sleep time
- The effect on sleep latency is minimal to modest 7, 8
Evidence for Efficacy Based on Mechanism
The 2017 AASM guidelines 7 demonstrate that at 3-6 mg doses:
- WASO reduction: 22-23 minutes greater than placebo (clinically significant)
- Total sleep time increase: 26-32 minutes longer than placebo (clinically significant)
- Sleep latency: Only 2-5 minutes improvement (not clinically significant)
- Sleep efficiency: Significant improvement exceeding clinical thresholds
Important Mechanistic Distinctions
Doxepin at low doses is NOT functioning as an antidepressant 9. The 2008 AASM guidelines explicitly note that when antidepressants like doxepin are used at "lower than antidepressant therapeutic dosages for the treatment of insomnia," they work through different mechanisms 9.
Key Pharmacologic Features
- No CNS stimulation: Not a central nervous system stimulant 1
- No MAO inhibition: Not a monoamine oxidase inhibitor 1
- No tolerance or dependence: At low doses, does not produce physical tolerance or psychological dependence typical of addictive compounds 1, 4
- Minimal anticholinergic effects: Unlike higher doses, low-dose doxepin has negligible anticholinergic activity 9
Practical Clinical Context
The FDA-approved low-dose formulation (3 mg and 6 mg) specifically leverages the H1 antagonism while avoiding the multi-receptor effects that cause side effects at antidepressant doses 1. This explains why:
- Adverse events at 3-6 mg are comparable to placebo 7, 6
- There is no next-day residual sedation 4, 10
- The drug is well-tolerated even in elderly patients 7, 6
The 2017 AASM guidelines recommend doxepin specifically for sleep maintenance insomnia 7, reflecting its mechanism of sustained H1 blockade throughout the night rather than rapid sleep induction.